Findings · MPN Watch

web other n2

FDA Rejects NDA for Extended-Release Jakafi - Managed Healthcare Executive

Within last 7 days

web other n1

MPN Challenge — MPN Research Foundation

September 2026

web review n2

Current and Emerging Therapies - MPN Research Foundation

Recent

web trial early n4

New Essential Thrombocythemia Treatment Appears to Address Underlying Disease

November 12, 2025

web review n2

Latest Advancements in Myelofibrosis Treatment: Key Updates from EHA and ASH 2025

May 30, 2026

web review n3

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

May 22, 2026

web review n3

CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management

May 21, 2026

web other n2

FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions

May 2026

web review n1

MPN Landscape Shifts from JAKi Monotherapy to Combining Novel Agents

May 20, 2026

web other n3

MPN | Tumor | CURE

May 17, 2026

web review n3

CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management

May 12, 2026

web review n3

Mutant calreticulin–directed immunotherapies in myeloproliferative neoplasms

May 1, 2026

web review n3

Myelofibrosis (MF) in 2026: Matching Therapy to the Dominant Clinical Problem

May 1, 2026

web other n4

NMPA Approved Drugs List – February 2026 Update

March 5, 2026

web review n3

NCCN Updates Guidance on Interferon in Essential Thrombocythemia

March 30, 2026

web trial early n5

ASH 2025: Myelofibrosis Roundup

March 24, 2026

web review n2

Essential Thrombocythemia and Polycythemia Vera Treatments Are Moving Toward Disease Modification

March 17, 2026

web other n1

MPN Research Foundation and Canadian MPN Research Foundation launch collaboration to improve outcomes for MPN patients

March 15, 2026

web review n2

The Science of CALR: From Mutation Discovery to Emerging Therapeutic Strategies – MPN United Webinar Series

June 3, 2026

web other n1

2026 Global Patient Unmet Needs Assessment – MPN Research Foundation

June 2026 (Ongoing)

web other n1

ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions

June 2025

web review n3

Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review

June 12-15, 2025

web other n3

Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis

January 21, 2026

web other n3

FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases

Foundation announcement (recent)

web other n3

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396

February 3, 2026

web other n4

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

February 3, 2026

web trial early n4

Early Data Show Mutant CALR-Specific Monoclonal Antibody Well Tolerated in Myelofibrosis

December 7, 2025 (ASH); reported Nov 24, 2025

web preclinical n4

Prelude Therapeutics Presents Data at 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm Programs

December 6, 2025

web review n2

ASH 2025 Highlights: Top Hematology Research Abstracts Selected by Field Experts

December 2025

web other n1

2nd EHA-SWG Scientific Meeting on MDS/MPN/AML - European Hematology Association

April 30-May 2, 2026

web trial early n4

Fedratinib Shows Promise in MDS/MPN Overlap Syndromes and CNL

April 28, 2026

web trial early n4

FDA Approves Pemazyre (Pemigatinib) for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

April 28, 2026

web trial early n4

Biomed Valley Discoveries Phase 1/2 Trial: Ulixertinib + Ruxolitinib for Myelofibrosis

April 28, 2025

web other n4

Lilly to Acquire Ajax Therapeutics for Next-Generation JAK2 Inhibitors in MPNs

April 27, 2026

web other n1

Honoring Dr. Richard T. Silver, MD - MPN Research Foundation

April 23, 2026

web trial early n3

Peri-Transplant Ruxolitinib Leads to Low GVHD Incidence in Myelofibrosis - OncLive

April 2, 2026

web review n2

CYTO-PV Trial Insights: Optimizing Hematocrit Targets - Targeted Oncology

April 15, 2026

web review n2

20th International Congress on Myeloproliferative Neoplasms - MPN Research Foundation Coverage

Approximately 2020-2021 (historical)

pubmed review n2

Ropeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.

30-oct-2026

pubmed observational n3

Long-term deepening of JAK2V617F molecular response with low-dose ropeginterferon in low-risk polycythaemia vera.

25-oct-2026

pubmed review n2

New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.

23-oct-2026

pubmed review n2

How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?

23-oct-2026

pubmed meta analysis n3

High Initial Dose and Accelerated vs. Slow Titration Ropeginterferon Alfa-2b for Polycythemia Vera: A Meta-Analysis.

21-oct-2026

pubmed review n4

"Beyond the Genetic Blueprint: Disrupting the Epitranscriptomic Code in Myeloproliferative Neoplasms".

16-oct-2026

pubmed trial late n3

VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.

13-oct-2026

web observational n2

Patients With MPNs Face Higher Cardiovascular Risks, in Addition to AML Risk

09-oct-2026

clinicaltrials observational n2

A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera

09-oct-2026

rss other n1

Can Heat or Cold Make My PV Symptoms Worse?

09-oct-2026

web other n1

A Patient's Journey With Essential Thrombocythemia and Polycythemia Vera

07-oct-2026

clinicaltrials observational n1

MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms

07-oct-2026

pubmed observational n3

Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.

07-oct-2026

pubmed preclinical n5

Aberrant erythrocyte rigidity in JAK2myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage.

07-oct-2026

clinicaltrials trial early n1

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

06-oct-2026

web review n1

Polycythemia Vera: 2024 Update on Diagnosis, Risk-Stratification, and Management

05-oct-2026

clinicaltrials trial early n3

A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera

05-oct-2026

pubmed case report n3

Momelotinib induces hemoglobin improvement and symptom control in PCM1::JAK2-associated myeloid neoplasm.

04-oct-2026

web trial late n3

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

04-oct-2026

clinicaltrials observational n2

Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia

01-oct-2026

clinicaltrials trial early n4

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms

30-sep-2026

rss other n1

From Counting Birthdays to Traveling Again

30-sep-2026

rss other n1

Beyond the Numbers: A Dad's Story

30-sep-2026

pubmed case report n2

Masked polycythaemia vera presenting with extensive splanchnic venous thrombosis and mesenteric ischaemia.

30-sep-2026

web other n4

Rusfertide Approval Expands Options and Improves Burdens in Polycythemia Vera

29-sep-2026

rss review n1

Myelofibrosis Anemia: More Options Than Ever

29-sep-2026

pubmed review n2

Megakaryocytes in myelofibrosis: mechanisms of fibrotic niche remodeling and therapeutic implications.

29-sep-2026

clinicaltrials trial early n2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

28-sep-2026

clinicaltrials trial early n4

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

28-sep-2026

pubmed review n2

PIM1 in myeloproliferative neoplasms: potential pathogenic and therapeutic implications.

28-sep-2026

pubmed review n2

Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM.

26-sep-2026

rss other n1

Polycythemia Vera Treatment: What to Expect

25-sep-2026

clinicaltrials observational n2

A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France

24-sep-2026

pubmed preclinical n5

Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.

24-sep-2026

rss other n1

How to Support a Loved One with PV

23-sep-2026

rss other n1

Coping With PV: Anxiety and Uncertainty

23-sep-2026

rss other n1

Living with PV: Navigating Daily Challenges

23-sep-2026

rss other n1

Living with PV: Finding Balance and Joy

23-sep-2026

clinicaltrials observational n2

Study of Pregnancy in Patients With Myeloproliferative Neoplasms

22-sep-2026

clinicaltrials observational n2

Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms

22-sep-2026

pubmed case report n2

Dual-Driver Myeloproliferative Neoplasm: Concurrent p190CML andV617F Mutation: A Case Report and Literature Review.

22-sep-2026

clinicaltrials trial early n3

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

21-sep-2026

rss review n1

Beyond Symptom Relief: MPN Treatment Goals

21-sep-2026

rss other n1

What Does Good Control Mean in Polycythemia Vera?

21-sep-2026

rss other n1

PV: How to Advocate for Your Care Needs

21-sep-2026

pubmed meta analysis n3

Clinicopathologic Characteristics of SomaticMutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

19-sep-2026

pubmed review n2

Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.

18-sep-2026

web review n1

Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update from MPN Asia 2026

17-sep-2026

clinicaltrials trial early n2

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

17-sep-2026

clinicaltrials trial early n2

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

16-sep-2026

clinicaltrials trial early n3

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

16-sep-2026

pubmed trial early n3

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.

16-sep-2026

clinicaltrials trial early n2

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

15-sep-2026

pubmed observational n2

Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval.

15-sep-2026

pubmed preclinical n4

Type 1 interferon perturbates clonal competition by reshaping human blood development.

15-sep-2026

clinicaltrials trial early n2

Haplo-HSCT for Myelofibrosis

14-sep-2026

pubmed review n1

Managing thrombotic risk in myeloproliferative disorders.

12-sep-2026

clinicaltrials trial early n3

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

11-sep-2026

clinicaltrials observational n1

Myeloproliferative Neoplasms: an In-depth Case-control Study

11-sep-2026

clinicaltrials observational n2

Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy

09-sep-2026

rss other n1

Pacritinib

08-sep-2026

rss other n1

Ojjaara

08-sep-2026

rss other n1

Jakafi

08-sep-2026

pubmed observational n3

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera.

08-sep-2026

pubmed other n2

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.

06-sep-2026

clinicaltrials trial early n3

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

04-sep-2026

clinicaltrials observational n2

Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type

04-sep-2026

rss other n1

MPN Voice Patients’ Forum – Leeds Wednesday 4th Nov 2026

Attend MPN Voice Patients’ Forum (Leeds) · 04-nov-2026 · 7 days ago · published 04-sep-2026

clinicaltrials trial early n3

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

03-sep-2026

pubmed preclinical n4

Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.

03-sep-2026

pubmed preclinical n4

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

01-sep-2026

web other n4

FDA Approves Mimrylo (rusfertide) for Polycythemia Vera

01-sep-2026

rss other n3

FDA Approves First Blood Cancer Drug in 30 Years

01-sep-2026

pubmed observational n2

Nurse-Led Patient-Reported Outcome Assessment of Symptom Burden and Quality of Life in Myeloproliferative Neoplasms: An Observational Study.

01-sep-2026

pubmed review n2

Dissecting Bone Marrow Fibrosis in Philadelphia-Negative Myeloproliferative Neoplasms: Multiple Roads Lead to Rome.

01-sep-2026

pubmed observational n4

Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.

01-sep-2026

pubmed observational n3

Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

01-sep-2026

pubmed preclinical n5

Type-I interferon-activated NK cells control polycythemia vera in vivo.

01-sep-2026

web other n1

September Is National Myeloproliferative Neoplasms Awareness Month

2026-09 (3 weeks ago)

web other n1

MPN Research Foundation 2026 Challenge Grant Awards

2026-09

web other n4

FDA Approves First-of-its-Kind Drug for Polycythemia Vera (Rusfertide/Mimrylo)

31-aug-2026

web other n3

FDA Approves PharmaEssentia's BESREMi (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia

31-aug-2026

rss other n1

You’re Not Alone: A Myelofibrosis Roadmap

31-aug-2026

pubmed review n2

From Immune Dysfunction to Clinical Risk: Infections in Myelofibrosis.

31-aug-2026

clinicaltrials trial early n2

A Study of Rusfertide in Adults With Polycythemia Vera in China

28-aug-2026

clinicaltrials trial early n2

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia

27-aug-2026

pubmed trial early n3

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

27-aug-2026

clinicaltrials trial early n2

Decitabine in Treating Patients With Myelofibrosis

26-aug-2026

pubmed review n2

Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.

26-aug-2026

pubmed case report n2

Synchronous Coexistence of JAK2 V617F-Positive Essential Thrombocythemia and IgG Kappa Multiple Myeloma in an Octogenarian Patient: A Case Report.

26-aug-2026

pubmed preclinical n5

Spatial profiling of the spleen in mouse and human myelofibrosis reveals complement-driven immune-stromal interactions as a therapeutic target.

25-aug-2026

pubmed observational n3

Sequential High-Dose Ruxolitinib and Low-Dose Splenic Irradiation for Pretransplant Management of Splenomegaly Before Allogeneic Hematopoietic Cell Transplantation With Fludarabine/Busulfan-Based Conditioning in Myelofibrosis.

23-aug-2026

pubmed review n2

Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities.

21-aug-2026

pubmed observational n3

Mutational landscape of classical myeloproliferative neoplasms in the Western Cape Province, South Africa.

20-aug-2026

clinicaltrials observational n2

Pacritinib Effectiveness in Real-world Settings

19-aug-2026

pubmed review n2

Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.

18-aug-2026

clinicaltrials trial early n3

Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)

18-aug-2026

pubmed observational n3

Immune and cytokine landscape differs between cytopenic and proliferative phenotypes in primary myelofibrosis.

18-aug-2026

pubmed observational n3

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

18-aug-2026

pubmed review n2

Malondialdehyde at the Crossroads of Oxidative Stress, Lipid Peroxidation, Ferroptosis, and Hematological Malignancies: A Narrative Review.

15-aug-2026

web trial early n3

Highlights From EHA 2026: The Latest Findings in Myeloproliferative Neoplasms

14-aug-2026

pubmed meta analysis n3

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.

14-aug-2026

clinicaltrials trial early n3

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

13-aug-2026

clinicaltrials trial late n3

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

13-aug-2026

clinicaltrials trial early n2

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

13-aug-2026

rss other n1

MPN Voice Patients’ Forum – Newcastle-upon-Tyne, Fri 9 Oct 2026

Attend MPN Voice Patients’ Forum (Newcastle) · 09-oct-2026 · 33 days ago · published 13-aug-2026

clinicaltrials trial early n2

A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

12-aug-2026

pubmed observational n3

Additional myelodysplasia-related gene mutations alter clinical presentation and worsen prognosis in patients with/co-mutated myeloid neoplasms.

12-aug-2026

clinicaltrials trial early n2

Pacritinib in CMML

11-aug-2026

clinicaltrials trial late n2

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

11-aug-2026

clinicaltrials observational n2

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes

10-aug-2026

clinicaltrials trial early n3

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

10-aug-2026

pubmed observational n2

Adolescent and Young Adult versus Older Adult Philadelphia-Negative Myeloproliferative Neoplasms: A Single-Center Experience from the MENA Region.

10-aug-2026

pubmed case report n2

Beyond the Bone Marrow: A Case Report of Extramedullary Hematopoiesis in Advanced Primary Myelofibrosis.

09-aug-2026

pubmed observational n3

Collagen Turnover Is Associated with Disease Severity, Bone Marrow Fibrosis, and theVariant Allele Frequency in Myeloproliferative Neoplasms.

06-aug-2026

clinicaltrials trial early n2

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

04-aug-2026

pubmed observational n3

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

04-aug-2026

web review n2

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting

03-aug-2026

pubmed observational n4

Spatially resolved transcriptomic profiling of myelofibrosis spleen reveals compartment specific niche programs.

03-aug-2026

pubmed observational n3

Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis.

03-aug-2026

pubmed review n2

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting.

03-aug-2026

pubmed observational n2

Patient-reported outcomes of symptom burden and quality of life in patients with polycythemia vera and essential thrombocythemia in Korea: A cross-sectional study.

01-aug-2026

pubmed trial early n4

Type II JAK2 Inhibitor Gets Off to a Strong Start.

01-aug-2026

pubmed trial early n3

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.

01-aug-2026

pubmed case report n2

Perioperative Management of Ruxolitinib in Primary Myelofibrosis During Coronary Artery Bypass Graft Surgery.

01-aug-2026

pubmed meta analysis n3

Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis.

01-aug-2026

pubmed observational n3

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

01-aug-2026

pubmed review n3

Inflammatory Network Architecture Across Bone Marrow Failure: An Immune-Genetic Continuum.

01-aug-2026

pubmed review n2

Myeloproliferative Neoplasms.

01-aug-2026

pubmed review n2

[Experimental model systems of primary myelofibrosis].

01-aug-2026

pubmed case report n2

Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review.

01-aug-2026

clinicaltrials observational n3

Quantitative MRI for Myelofibrosis

31-jul-2026

clinicaltrials trial early n1

Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera

31-jul-2026

pubmed observational n3

Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms.

31-jul-2026

pubmed case report n2

Management of BK Polyomavirus in a Kidney Transplant Recipient With Primary Myelofibrosis on JAK-2 Inhibition - A Case Report and Literature Review.

31-jul-2026

pubmed review n2

Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.

30-jul-2026

pubmed other n1

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

30-jul-2026

clinicaltrials trial early n3

Revumenib in Patients With Myelofibrosis

29-jul-2026

clinicaltrials other n1

Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative

29-jul-2026

clinicaltrials trial early n2

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

28-jul-2026

pubmed observational n2

Comparative Evaluation of Quantitative Real-Time PCR and a Laboratory-Developed Chip-Based Real-Time Digital PCR forV617F Allele Burden in Myeloproliferative Neoplasms.

25-jul-2026

pubmed case report n2

Dengue Fever Unmasking JAK2 Mutation-Related Polycythemia Vera Presenting With Extensive Splanchnic Venous Thrombosis and Hemorrhagic Complications: A Diagnostic and Therapeutic Challenge.

25-jul-2026

pubmed case report n2

Case Report: Polycythemia vera presenting as persistent unexplained low-grade fever.

24-jul-2026

pubmed review n2

SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis.

24-jul-2026

clinicaltrials trial early n2

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

23-jul-2026

pubmed observational n3

DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia.

23-jul-2026

pubmed review n2

SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis.

23-jul-2026

pubmed observational n3

Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b.

23-jul-2026

pubmed case report n3

Hyperviscosity encephalopathy in suspected polycythemia vera at high altitude: a case report.

23-jul-2026

clinicaltrials trial late n3

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

22-jul-2026

pubmed observational n3

Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study.

22-jul-2026

web other n2

FDA Grants Priority Review to Rusfertide for Polycythemia Vera

21-jul-2026

rss other n1

MF, Anemia, and the Real Cost of Cancer Care

21-jul-2026

pubmed review n2

Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.

21-jul-2026

clinicaltrials trial early n3

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

20-jul-2026

clinicaltrials trial early n3

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

20-jul-2026

pubmed case report n2

Case Report: Chronic myeloid leukemia masquerading as essential thrombocythemia in a child: the imperative for early BCR::ABL1 testing in isolated thrombocytosis.

20-jul-2026

pubmed review n2

Dose schedule modifications of 5-azacitidine monotherapy in myelodysplastic neoplasias and chronic myelomonocytic leukaemia.

19-jul-2026

pubmed observational n3

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

18-jul-2026

clinicaltrials trial late n2

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

17-jul-2026

pubmed observational n3

Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?

17-jul-2026

pubmed review n2

The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting.

17-jul-2026